Frias JP, Deenadayalan S, Erichsen L, Knop FK, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023 Jun 23:S0140-6736(23)01163-7. doi: 10.1016/S0140-6736(23)01163.
PMID: 37364590